Fertin Pharma Reshapes India Leadership Amid CDMO Ambitions

Fertin Pharma has appointed Aditya Sharma as Managing Director for its India operations, a move that positions the Denmark-headquartered CDMO to deepen its manufacturing and commercial presence in one of the world's most competitive pharmaceutical markets. For contract manufacturing organisations watching capacity allocation and regional leadership structures, the appointment signals a deliberate organisational investment in the subcontinent.

Sharma brings a background spanning business transformation, commercial strategy, and growth leadership within the healthcare and consumer wellness sectors. His profile aligns with the dual mandate Fertin India faces: scaling CDMO service offerings while navigating the regulatory and operational complexity that defines Indian pharmaceutical manufacturing under frameworks such as 21 CFR Part 211 and Schedule M compliance requirements.

Fertin Pharma has built its reputation on drug delivery formats including oral thin films, chewing gum-based therapeutics, and other non-traditional dosage forms. Appointing a Managing Director with a commercial and transformation background, rather than a purely technical one, suggests the India entity may be prioritising business development and partnership pipelines alongside manufacturing scale-up. QA directors and regulatory affairs leads at potential partner organisations should note the strategic intent embedded in this hire.

No specific expansion targets, facility investments, or client pipeline details were disclosed at the time of appointment. The practical implications for contract manufacturing partners, technology transfer timelines, or site-level GMP governance changes remain to be confirmed as Sharma assumes the role.

Source: Media4Growth / Indian Pharma Post, published 3 May 2026.